Home > Research > Publications & Outputs > Dietary flavonoids inhibit the anticancer effec...

Links

Text available via DOI:

View graph of relations

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. / Liu, F.-T.; Agrawal, S.G.; Movasaghi, Z. et al.

In: Blood, Vol. 112, No. 9, 2008, p. 3835-3846.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Liu, F-T, Agrawal, SG, Movasaghi, Z, Wyatt, PB, Rehman, IU, Gribben, JG, Newland, AC & Jia, L 2008, 'Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib', Blood, vol. 112, no. 9, pp. 3835-3846. https://doi.org/10.1182/blood-2008-04-150227

APA

Liu, F-T., Agrawal, S. G., Movasaghi, Z., Wyatt, P. B., Rehman, I. U., Gribben, J. G., Newland, A. C., & Jia, L. (2008). Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood, 112(9), 3835-3846. https://doi.org/10.1182/blood-2008-04-150227

Vancouver

Liu F-T, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, Gribben JG et al. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood. 2008;112(9):3835-3846. doi: 10.1182/blood-2008-04-150227

Author

Liu, F.-T. ; Agrawal, S.G. ; Movasaghi, Z. et al. / Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. In: Blood. 2008 ; Vol. 112, No. 9. pp. 3835-3846.

Bibtex

@article{899929b42ded412cb81b1316be32e16f,
title = "Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib",
abstract = "Dietary flavonolds have many health-promoting actions, including anticancer activity via proteasome inhibition. Bortezomib is a dipeptide boronate proteasome inhibitor that has activity in the treatment of multiple myeloma but Is not effective In chronic lymphocytic leukemia (CLL). Although CLL cells are sensitive In vitro to bortezomlb-induced apoptosis when cultured in medium, the killing activity was blocked when cultured In 50% fresh autologous plasma. Dietary flavonoids, quercetin and myrocetin, which are abundant In plasma, inhibited bortezomib-induced apoptosis of primary CLL and malignant B-cell lines in a dose-dependent manner. This inhibitory effect was associated with chemical reactions between quercetin and the boronic acid group, -RB(OH) 2 , in bortezomib. The addition of boric acid diminished the inhibitory effect of both quercetin and plasma on bortezomib-induced apoptosis. The protective effect was also reduced when myeloma cell lines, but not B-cell lines, were preincubated with quercetin, indicating a direct effect of quercetin on myeloma cells. At high doses, quercetin itself induced tumor cell death. These data indicate that dietary flavonoids limit the efficacy of bortezomib, whereas supplemental inorganic boric acid is able to reverse this. The complex interactions between quercetin, tumor cells, and bortezomib mean caution Is required when giving dietary advice to patients. {\textcopyright} 2008 by The American Society of Hematology.",
keywords = "acetylcysteine, apigenin, benzyloxycarbonylleucylleucylleucinal, boric acid, bortezomib, caspase 3, caspase 8, caspase 9, curcumin, cytochrome c, delphinidin, epigallocatechin, epigallocatechin gallate, flavonoid, functional group, kaempferol, mg 262, myricetin, protein Bax, quercetin, reactive oxygen metabolite, resveratrol, unclassified drug, antineoplastic agent, BAX protein, human, boronic acid derivative, proteinase inhibitor, pyrazine derivative, scavenger, antineoplastic activity, antioxidant activity, apoptosis, article, B lymphocyte, cell death, chemical reaction, chronic lymphatic leukemia, concentration response, controlled study, diet supplementation, drug blood level, drug effect, drug efficacy, drug inhibition, drug structure, enzyme activity, human, human cell, IC 50, myeloma cell, plasma, priority journal, protein secretion, upregulation, B cell leukemia, B cell lymphoma, cell line, diet, diet therapy, drug antagonism, in vitro study, metabolism, multiple myeloma, pathology, tumor cell line, Antineoplastic Agents, Apoptosis, bcl-2-Associated X Protein, Boric Acids, Boronic Acids, Cell Line, Transformed, Cell Line, Tumor, Cytochromes c, Diet, Flavonoids, Free Radical Scavengers, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Multiple Myeloma, Protease Inhibitors, Pyrazines, Quercetin",
author = "F.-T. Liu and S.G. Agrawal and Z. Movasaghi and P.B. Wyatt and I.U. Rehman and J.G. Gribben and A.C. Newland and L. Jia",
year = "2008",
doi = "10.1182/blood-2008-04-150227",
language = "English",
volume = "112",
pages = "3835--3846",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

RIS

TY - JOUR

T1 - Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

AU - Liu, F.-T.

AU - Agrawal, S.G.

AU - Movasaghi, Z.

AU - Wyatt, P.B.

AU - Rehman, I.U.

AU - Gribben, J.G.

AU - Newland, A.C.

AU - Jia, L.

PY - 2008

Y1 - 2008

N2 - Dietary flavonolds have many health-promoting actions, including anticancer activity via proteasome inhibition. Bortezomib is a dipeptide boronate proteasome inhibitor that has activity in the treatment of multiple myeloma but Is not effective In chronic lymphocytic leukemia (CLL). Although CLL cells are sensitive In vitro to bortezomlb-induced apoptosis when cultured in medium, the killing activity was blocked when cultured In 50% fresh autologous plasma. Dietary flavonoids, quercetin and myrocetin, which are abundant In plasma, inhibited bortezomib-induced apoptosis of primary CLL and malignant B-cell lines in a dose-dependent manner. This inhibitory effect was associated with chemical reactions between quercetin and the boronic acid group, -RB(OH) 2 , in bortezomib. The addition of boric acid diminished the inhibitory effect of both quercetin and plasma on bortezomib-induced apoptosis. The protective effect was also reduced when myeloma cell lines, but not B-cell lines, were preincubated with quercetin, indicating a direct effect of quercetin on myeloma cells. At high doses, quercetin itself induced tumor cell death. These data indicate that dietary flavonoids limit the efficacy of bortezomib, whereas supplemental inorganic boric acid is able to reverse this. The complex interactions between quercetin, tumor cells, and bortezomib mean caution Is required when giving dietary advice to patients. © 2008 by The American Society of Hematology.

AB - Dietary flavonolds have many health-promoting actions, including anticancer activity via proteasome inhibition. Bortezomib is a dipeptide boronate proteasome inhibitor that has activity in the treatment of multiple myeloma but Is not effective In chronic lymphocytic leukemia (CLL). Although CLL cells are sensitive In vitro to bortezomlb-induced apoptosis when cultured in medium, the killing activity was blocked when cultured In 50% fresh autologous plasma. Dietary flavonoids, quercetin and myrocetin, which are abundant In plasma, inhibited bortezomib-induced apoptosis of primary CLL and malignant B-cell lines in a dose-dependent manner. This inhibitory effect was associated with chemical reactions between quercetin and the boronic acid group, -RB(OH) 2 , in bortezomib. The addition of boric acid diminished the inhibitory effect of both quercetin and plasma on bortezomib-induced apoptosis. The protective effect was also reduced when myeloma cell lines, but not B-cell lines, were preincubated with quercetin, indicating a direct effect of quercetin on myeloma cells. At high doses, quercetin itself induced tumor cell death. These data indicate that dietary flavonoids limit the efficacy of bortezomib, whereas supplemental inorganic boric acid is able to reverse this. The complex interactions between quercetin, tumor cells, and bortezomib mean caution Is required when giving dietary advice to patients. © 2008 by The American Society of Hematology.

KW - acetylcysteine

KW - apigenin

KW - benzyloxycarbonylleucylleucylleucinal

KW - boric acid

KW - bortezomib

KW - caspase 3

KW - caspase 8

KW - caspase 9

KW - curcumin

KW - cytochrome c

KW - delphinidin

KW - epigallocatechin

KW - epigallocatechin gallate

KW - flavonoid

KW - functional group

KW - kaempferol

KW - mg 262

KW - myricetin

KW - protein Bax

KW - quercetin

KW - reactive oxygen metabolite

KW - resveratrol

KW - unclassified drug

KW - antineoplastic agent

KW - BAX protein, human

KW - boronic acid derivative

KW - proteinase inhibitor

KW - pyrazine derivative

KW - scavenger

KW - antineoplastic activity

KW - antioxidant activity

KW - apoptosis

KW - article

KW - B lymphocyte

KW - cell death

KW - chemical reaction

KW - chronic lymphatic leukemia

KW - concentration response

KW - controlled study

KW - diet supplementation

KW - drug blood level

KW - drug effect

KW - drug efficacy

KW - drug inhibition

KW - drug structure

KW - enzyme activity

KW - human

KW - human cell

KW - IC 50

KW - myeloma cell

KW - plasma

KW - priority journal

KW - protein secretion

KW - upregulation

KW - B cell leukemia

KW - B cell lymphoma

KW - cell line

KW - diet

KW - diet therapy

KW - drug antagonism

KW - in vitro study

KW - metabolism

KW - multiple myeloma

KW - pathology

KW - tumor cell line

KW - Antineoplastic Agents

KW - Apoptosis

KW - bcl-2-Associated X Protein

KW - Boric Acids

KW - Boronic Acids

KW - Cell Line, Transformed

KW - Cell Line, Tumor

KW - Cytochromes c

KW - Diet

KW - Flavonoids

KW - Free Radical Scavengers

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Lymphoma, B-Cell

KW - Multiple Myeloma

KW - Protease Inhibitors

KW - Pyrazines

KW - Quercetin

U2 - 10.1182/blood-2008-04-150227

DO - 10.1182/blood-2008-04-150227

M3 - Journal article

VL - 112

SP - 3835

EP - 3846

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -